Andrew A. Nierenberg, M.D.

Dr. Andrew Nierenberg graduated from the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY. After completing his residency in psychiatry at New York University/Bellevue Hospital, he studied clinical epidemiology at Yale University as a Robert Wood Johnson Clinical Scholar. Dr. Nierenberg then joined the faculty at Harvard Medical School, first at McLean Hospital in Belmont, Massachusetts and then at Massachusetts General Hospital, where he holds the Thomas P. Hackett MD Endowed Chair in Psychiatry and is a professor of psychiatry at Harvard Medical School. He is also Honorary Professor in the School of Medicine, Faculty of Health at Deakin University, Geelong Australia (where he was a Thinker in Residence), and Honorary Skou Professor at Aarhus University in Denmark.

Dr. Nierenberg has published over 500 papers and has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994. In 2000, he was awarded the Gerald L. Klerman Young Investigator Award and in 2014 the Gerald L. Klerman Senior Investigator Award by the Depression Bipolar Support Alliance. In 2013, Dr. Nierenberg was awarded the prestigious Brain and Behavior Research Foundation Colvin Prize for outstanding achievement in mood disorders research. In 2014, he was awarded the Mentorship Award for Exceptional Mentorship in the Research Arena at MGH. In 2014, 2015, 2016, and 2017, he was listed among the World’s Most Influential Scientific Minds by Clarivate in recognition of ranking among the top 1% of researchers for most cited papers in psychiatry worldwide, currently with over 25,000 citations and an h-factor of greater than 80. In 2020, Dr. Nierenberg was given the International Society of Bipolar Disorder Mogen Schou Research Award, the highest award given by ISBD.

Dr. Nierenberg was on the leadership teams of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) and the Sequential Treatment Alternatives to Relieve Depression (STAR*D) National Institute of Mental Health (NIMH) contracts, clinical trials that included thousands of patients with mood disorders. He then led the Bipolar Trials Network to conduct comparative effectiveness studies (LiTMUS and Bipolar CHOICE). He established the Dauten Family Center for Bipolar Treatment Innovation at MGH in 2018 which has an endowment to focus on finding better treatments to get better outcomes.

Dr. Nierenberg’s primary interest is innovative treatments for bipolar disorder. He lectures extensively, both nationally and internationally, teaches, supervises, maintains an active clinical practice, consults to industry, and conducts clinical trials funded by federal, foundation, industry, and philanthropic sources. He serves as a peer reviewer for over 35 psychiatric journals. He is a member of the editorial boards of over 15 journals including the Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, Journal of Affective Disorders, Australian New Zealand Journal of Psychiatry, and Bipolar Disorders. Dr. Nierenberg is a deputy editor of Depression and Anxiety and editor of Psychiatric Annals.

Skip to content